Vexim Release: Sharp Increase in Sales Over the 1st Half of 2013: +133% to €2.5 Million
7/22/2013 10:51:24 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Toulouse, July 22nd 2013 - VEXIM (FR0011072602 - ALVXM), a medical device company
specializing in the minimally-invasive treatment of vertebral fractures, today announces its
consolidated sales for the half year to June 30th 2013.
Buoyant increase in sales over the 1st half of 2013
The acceleration in VEXIM’s growth continued strongly over the 1st half of 2013, with sales
substantially more than doubling (+133%) to €2.5 million. This sound performance is the
result of VEXIM’s successful direct marketing strategy (94% of total sales in H1 2013,
compared with 68% in H1 2012) to support the strong demand for the SpineJack® from
physicians. Indeed, with more than 1,900 implants inserted over the 1st half of 2013, and
6,300 since its launch, the adoption of the SpineJack® by European and international
surgeons is continually increasing.
Very dynamic activity on all of VEXIM’s markets
VEXIM’s sales activity has been extremely strong in France (+150% compared with H1 2012)
and abroad (+121% compared with H1 2012). International growth over the first half of the
year was driven by the dynamism of the German and Italian markets, directly covered by
VEXIM for a year now, and the initial contributions of Spain and the United Kingdom, where
subsidiaries opened at the beginning of this year. The half-year sales recorded by these
European subsidiaries totaled €1.1 million, compared with €971 thousand over the whole
Vincent Gardès, CEO of VEXIM, concludes: “Following a doubling of our sales over the 1st
quarter of 2013, our sales momentum is continuing to intensify, as shown by the strength of
our activity over the first half. All of the markets in which we are present are delivering
excellent performances and represent a solid base for our future development. I would like to
thank all our staff for their contribution to the implementation of VEXIM’s strategy that aims
to make the company the European leader in innovative back microsurgery.”
About Vexim, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting
from the financial support of its longstanding shareholders, Truffle Capital1 and Banexi Venture, and from OSEO public
subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra
and restoring the balance of the spinal column. The Company currently has 48 staff. It has its own sales teams in France,
Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Turkey, Argentina, India,
Taiwan and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. Vexim has been listed on NYSE Alternext Paris since May 3rd 2012.
For further information, please go to www.vexim.com
SpineJack®2, a revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the
spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities.
Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery,
guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack®
range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and
all patient morphologies.
SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and
worldwide patent protection through to 2029.
Tel: +33 5 61 48 48 38
and Investor Relations
Dusan Oresansky /
Tel: +33 1 44 71 94 92
Tel: +33 6 64 18 99 59
Tel: +33 1 70 22 53 86
Help employers find you! Check out all the jobs and post your resume.
comments powered by